ArticleeLife2021
Epigenome-wide analysis of DNA methylation and coronary heart disease: a nested case-control study.
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Accelerated epigenetic age in hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Pooled it
- Integrative eQTL and Mendelian Randomization Analyses with Experimental Validation Prioritize Genetic Candidate Biomarkers for Crohn's Disease.Endocrine, metabolic & immune disorders drug targets · 2026Article
- An Integrative Polygenic and Epigenetic Risk Score for Overweight-related Hypertension in Chinese Population.Genomics, proteomics & bioinformatics · 2025Article
- Novel approaches and applications in identifying DNA methylation markers of cardio-kidney-metabolic disease.Epigenomics · 2025Review
- Personalized medicine for cardiovascular diseases: how next generation epigenetic technologies can contribute?Epigenomics · 2025Review
- Cardiometabolic disease management: influences from epigenetics.Epigenomics · 2025Review
- DNA methylation-based age prediction and sex-specific epigenetic aging in a lizard with female-biased longevity.Science advances · 2025Article
- Genome-wide DNA methylation profiling in blood reveals epigenetic signature of incident acute coronary syndrome.Nature communications · 2024Article
- Genotyping and population characteristics of the China Kadoorie Biobank.Cell genomics · 2023Article
- EpiMix is an integrative tool for epigenomic subtyping using DNA methylation.Cell reports methods · 2023Article
- A longitudinal study of the association between attending cultural events and coronary heart disease.Communications medicine · 2023Article
- Healthy lifestyle, DNA methylation age acceleration, and incident risk of coronary heart disease.Clinical epigenetics · 2023Article
- Association between attending cultural events and all-cause mortality: a longitudinal study with three measurements (1982-2017).BMJ open · 2023Article
- From 'Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators.Current atherosclerosis reports · 2023Review
- EpiMix: an integrative tool for epigenomic subtyping using DNA methylation.bioRxiv : the preprint server for biology · 2023Article
- Temporal associations between leukocytes DNA methylation and blood lipids: a longitudinal study.Clinical epigenetics · 2022Article
- Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease.Nature communications · 2022Article
- Epigenetics in Precision Nutrition.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 8 institutions in 4 countries.
Funding
Abstract
Background: Identifying environmentally responsive genetic loci where DNA methylation is associated with coronary heart disease (CHD) may reveal novel pathways or therapeutic targets for CHD. We conducted the first prospective epigenome-wide analysis of DNA methylation in relation to incident CHD in the Asian population. Methods: We did a nested case-control study comprising incident CHD cases and 1:1 matched controls who were identified from the 10 year follow-up of the China Kadoorie Biobank. Methylation level of baseline blood leukocyte DNA was measured by Infinium Methylation EPIC BeadChip. We performed the single cytosine-phosphate-guanine (CpG) site association analysis and network approach to identify CHD-associated CpG sites and co-methylation gene module. Results: After quality control, 982 participants (mean age 50.1 years) were retained. Methylation level at 25 CpG sites across the genome was associated with incident CHD (genome-wide false discovery rate [FDR] < 0.05 or module-specific FDR < 0.01). One SD increase in methylation level of identified CpGs was associated with differences in CHD risk, ranging from a 47 % decrease to a 118 % increase. Mediation analyses revealed 28.5 % of the excessed CHD risk associated with smoking was mediated by methylation level at the promoter region of Conclusions: We identified novel blood methylation alterations associated with incident CHD in the Asian population and provided evidence of the possible role of epigenetic regulations in the smoking- and blood pressure-related pathways to CHD risk. Funding: This work was supported by National Natural Science Foundation of China (81390544 and 91846303). The CKB baseline survey and the first re-survey were supported by a grant from the Kadoorie Charitable Foundation in Hong Kong. The long-term follow-up is supported by grants from the UK Wellcome Trust (202922/Z/16/Z, 088158/Z/09/Z, 104085/Z/14/Z), grant (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904) from the National Key R&D Program of China, and Chinese Ministry of Science and Technology (2011BAI09B01).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.